Skip to content

Released Mar 30, 2023, after the close

10-K filed Mar 30, 2023, 89 days after period end · 0000950170-23-011000

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$1.21MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$1,218,327N/M
Operating Cash Flowderived-$947,467N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Net Income-$1.21M-$3.86M-$1.62M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR